Pfizer, Merck KGaA: Bavencio Misses Main Endpoint in Gastric Cancer Study
November 08 2019 - 09:00AM
Dow Jones News
By Colin Kellaher
Pfizer Inc. (PFE) and Merck KGaA's (MRK.XE) EMD Serono unit on
Friday said a phase III study of the immunotherapy Bavencio in
gastric cancer didn't meet its primary endpoint.
The companies said Bavencio showed clinical activity in the
study, which evaluated the drug as first-line maintenance therapy
following induction chemotherapy in patients with unresectable,
locally advanced or metastatic HER2-negative gastric or
gastroesophageal junction cancer versus continuation of
chemotherapy or best supportive care.
However, Bavencio didn't meet the primary endpoints of superior
overall survival compared with the standard of care in the overall
intent-to-treat population or the PD-L1--positive population.
Germany's Merck and New York-based Pfizer formed a strategic
alliance in 2014 to jointly develop and commercialize Bavencio.
The drug is currently approved in 50 countries for patients with
the skin cancer Merkel cell carcinoma.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
November 08, 2019 08:45 ET (13:45 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
Merck KGaA (PK) (USOTC:MKKGY)
Historical Stock Chart
From Dec 2020 to Jan 2021
Merck KGaA (PK) (USOTC:MKKGY)
Historical Stock Chart
From Jan 2020 to Jan 2021